Dong-Yu Fan

Dong-Yu Fan

Auto-generated profile, based on publicly available information

Dong-Yu Fan

Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Science Advances
Verified
Journal Article
Open access
XBXian-Le Bu
Xian-Le Bu
PSPu-Yang Sun
Pu-Yang Sun
DFDong-Yu Fan
Dong-Yu Fan
JWJun Wang
Jun Wang
HSHao-Lun Sun
Hao-Lun Sun
YWYanjiang Wang
Yanjiang Wang
CD22 has been suggested to contribute to Alzheimer’s disease (AD) pathogenesis by inhibiting microglial amyloid β (Aβ) phagocytosis. Soluble CD22 (sCD22) generated by cleavage from cell membranes may be a marker of inflammation and microglial dysfunction; but alterations of sCD22 levels in AD and their correlation with AD biomarkers remain unclear. Plasma sCD22 levels were measured in cognitively normal non-AD participants and patients with preclinical AD and AD dementia from a Chinese cohort and the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Plasma sCD22 levels were elevated in patients with preclinical and dementia AD. Plasma sCD22 levels were negatively correlated with cerebrospinal fluid (CSF) Aβ42 levels and Aβ42/Aβ40, and positively correlated with CSF phosphorylated tau levels and brain Aβ burden, but negatively correlated with cognitive function. Moreover, higher plasma sCD22 levels were associated with faster cognitive decline during follow-up. These findings suggest that CD22 plays important roles in AD development, and that sCD22 is a potential biomarker for AD.

20 March 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
JJJie-Ming Jian
Jie-Ming Jian
XLXin-Peng Li
Xin-Peng Li
JXJun-Hao Xie
Jun-Hao Xie
JHJian-Ni Hu
Jian-Ni Hu
JLJun Liang
Jun Liang
HSHao-Lun Sun
Hao-Lun Sun
Background: Chronic hypoxia has been acknowledged as a significant risk factor for Alzheimer's disease (AD), yet the impact of high-altitude hypoxia on AD pathogenesis remains poorly understood. Objective: This study aims to investigate the effects of chronic high-altitude hypoxia on cognitive function and AD-related pathology. Methods: A cross-sectional cohort comprising 186 high-altitude migrants (HAM) and 378 high-altitude natives (HAN) was recruited for a preliminary assessment. We further conducted 101 HAM, 135 HAN, and 66 low-altitude controls (LA) for plasma biomarkers research. Plasma Aβ 40 , Aβ 42 , and T-tau levels were quantified by SIMOA. In parallel, APP/PS1 mice were exposed to hypobaric hypoxia (simulated at 5,500 m) or normoxia for 30 days, followed by behavioral tests, brain immunohistochemistry, and transcriptomic/proteomic analyses. Results: HAM subjects exhibited significant deficits in Montreal Cognitive Assessment scores and delayed recall subscores compared to LA controls, with both measures showing a positive correlation with peripheral oxygen saturation (SpO₂). Notably, HAN showed preserved memory despite lower overall cognitive scores. Plasma levels of amyloid-β (Aβ) 40 , Aβ 42 , and Aβ 42 /Aβ 40 ratio were significantly lower in both HAM and HAN groups compared to the LA group. In mice, chronic hypoxia exacerbated hippocampal Aβ deposition and induced spatial memory decline. Multi-omics analyses revealed the upregulation of oxidative stress and neuroinflammatory pathways and identified S100A8/A9 as a potential key mediator in hypoxia-accelerated AD pathology. Conclusions: Our findings demonstrate that chronic high-altitude hypoxia contributes to cognitive decline and AD-related pathological changes, likely mediated by Aβ burden and oxidative stress. High-altitude hypoxia might be an important environmental risk factor for AD.

16 February 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
ZCZu-Qi Chen
Zu-Qi Chen
MWMeng-Ting Wang
Meng-Ting Wang
CTCheng-Rong Tan
Cheng-Rong Tan
SHShan Huang
Shan Huang
FZFa-Ying Zhou
Fa-Ying Zhou
YWYanjiang Wang
Yanjiang Wang
Background: A disintegrin and metalloproteinase 17 (ADAM-17) has multiple pathophysiological functions in Alzheimer's disease (AD). However, the clinical relevance of ADAM-17 in AD is not clear yet. Objective: This study aims to investigate the levels of circulating ADAM-17 and their association with AD. Methods: This cross-sectional study recruited 40 normal cognition (NC) participants and 36 AD patients. Plasma ADAM-17 and biomarkers of neurodegeneration were determined. The association of plasma ADAM-17 with cognitive functions and biomarkers of neurodegeneration was analyzed. Results: Plasma ADAM-17 levels were elevated in AD patients in comparison with NC subjects. Plasma ADAM-17 was positively associated with Clinical Dementia Rating (CDR) scores, but negatively associated with the Mini-Mental State Examination scores and Montreal Cognitive Assessment scores. Plasma ADAM-17 levels were positively associated with the levels of Aβ 40 , Aβ 42 , and p-Tau181. Conclusions: These findings suggest a link between ADAM-17 and the pathogenesis of AD from a clinical perspective.